Furthermore, PRDX1 level was found to predict poor patient survival in non-small cell lung, ovarian, and breast cancers [30-32], and PRDX3 and PRDX4 expression were correlated with poor prognosis in hepatocellular carcinoma and squamous cell carcinoma respectively [33, 34]. This evidence concerns the gene PRDX3 and hepatocellular carcinoma.